Press "Enter" to skip to content

Drug Body Approves Commercial Launch of Low Cost Covid-19 Test ‘Feluda’

Image just for illustration. (AP Photo)

The Tata CRISPR check achieves accuracy ranges of conventional RT-PCR assessments with faster turnaround time, inexpensive gear and higher ease of use.

  • PTI New Delhi
  • Last Updated: September 19, 2020, 11:40 PM IST

  • FOLLOW US ON:

The Drugs Controller General of India has accredited the business launch of ’Feluda’, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Covid-19 check, the Council of Scientific and Industrial Research (CSIR) mentioned on Saturday. This check makes use of an indigenously developed, cutting-edge CRISPR expertise for detection of the genomic sequence of SARS-CoV-2 virus, CSIR mentioned in a press release.

The Tata CRISPR check achieves accuracy ranges of conventional RT-PCR assessments with faster turnaround time, inexpensive gear and higher ease of use. CRISPR is a genome modifying expertise to diagnose illnesses. The expertise has been developed by CSIR-IGIB (Institute of Genomics and Integrative Biology).






”The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) check, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA, obtained regulatory approvals at this time from DCGI for business launch, as per ICMR pointers, assembly prime quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting novel coronavirus,” the assertion mentioned. The Tata CRISPR check is the world’s first diagnostic check to deploy a specifically tailored Cas9 protein to efficiently detect the virus inflicting Covid-19, it mentioned.

Moreover, CRISPR is a futuristic expertise that can be configured for detection of a number of different pathogens sooner or later. ”The Tata Group has labored carefully with CSIR-IGIB and ICMR to create a high-quality check that can assist the nation ramp up COVID-19 testing shortly and economically, with a ’Made in India’ product that’s protected, dependable, reasonably priced and accessible,” the assertion added. Commenting on the event, Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd mentioned, ”The approval for the Tata CRISPR check for COVID-19 will strengthen the nation’s efforts in combating the worldwide pandemic.

”The commercialisation of Tata CRISPR check displays the great R&D expertise within the nation which might collaborate to remodel India’s contributions to the worldwide healthcare and scientific analysis world,” he mentioned. Anurag Agrawal, director, CSIR-IGIB, mentioned the work began by CSIR underneath the sickle cell mission for genome diagnostics and therapeutics led to new information that may very well be harnessed to shortly develop new diagnostic check for SARS-CoV-2. He emphasised that this reveals the interconnectedness of scientific information and expertise and the innovation of the younger analysis crew led by Debojyoti Chakraborty and Souvik Maiti.


Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    %d bloggers like this: